A fast-growing Eli Lilly med may be held back by a new warning linking it to acute pancreatitis. After 30 reports of pancreatitis in patients using the injectable diabetes drug Byetta--five of which led to serious complications such as kidney failure--the FDA has asked Lilly and its partner on the drug, Amylin [1], to revise its labeling.
With $430.2 million in 2006 sales, Byetta delivered some $219 million in revenues to Lilly. The rest went to Amylin, accounting for 90 percent of that company's sales. Amylin stock fell sharply on the news.
- check out the report [2] from the Indianapolis Star
Related Articles:
In speech, Lilly CEO calls for drug monitoring. Report [3]
Lilly developing biotech drugs the old-fashioned way. Report [4]
Amylin shares shoot up on Phase II Byetta results. Report [5]
Diabetes epidemic triggers soaring drug market. Report [6]
Links:
[1] http://www.fiercebiotech.com/tags/amylin-pharmaceuticals
[2] http://www.indystar.com/apps/pbcs.dll/article?AID=/20071017/BUSINESS/710170404/-1/LOCAL17
[3] http://www.fiercebiotech.com/story/speech-lilly-ceo-calls-drug-monitoring/2007-10-03
[4] http://www.fiercebiotech.com/story/lilly-developing-biotech-drugs-old-fashioned-way/2007-07-31
[5] http://www.fiercebiotech.com/story/amylin-shares-shoot-up-on-phase-ii-byetta-results/2005-08-23
[6] http://www.fiercebiotech.com/story/diabetes-epidemic-triggers-soaring-drug-market/2006-06-22
[7] http://www.fiercebiotech.com/tags/eli-lilly
[8] http://www.fiercebioresearcher.com/tags/diabetics